At the time of writing, Avidity Biosciences Inc. [RNA] stock is trading at $23.29, up 5.29%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The RNA shares have gain 5.86% over the last week, with a monthly amount glided 14.50%, and seem to be holding up well over a long-time horizon.
On 20, January 2023, Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4). In a post published today on Yahoo Finance, Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that on January 20, 2023, the Compensation Committee of Avidity’s Board of Directors granted non-qualified stock option awards to purchase an aggregate of 12,350 shares of its common stock and 6,175 restricted stock units (“RSUs”) to three new non-executive employees under the Avidity Biosciences, Inc. 2022 Employment Inducement Incentive Award Plan (the “2022 Inducement Plan”). The awards were granted as inducements material to the employees entering into employment with Avidity in accordance with Nasdaq Listing Rule 5635(c)(4).
From an analyst’s perspective:
Avidity Biosciences Inc. [NASDAQ: RNA] stock has seen the most recent analyst activity on July 20, 2022, when Chardan Capital Markets initiated its Buy rating and assigned the stock a price target of $29. Previously, Raymond James started tracking the stock with Strong Buy rating on July 12, 2022, and set its price target to $29. On September 07, 2021, Evercore ISI initiated with a Outperform rating and assigned a price target of $50 on the stock. Needham started tracking the stock assigning a Buy rating and suggested a price target of $50 on June 17, 2021. Wells Fargo started tracking with a Overweight rating for this stock on July 07, 2020, and assigned it a price target of $60. In a note dated July 07, 2020, Wells Fargo initiated an Overweight rating.
For the past year, the stock price of Avidity Biosciences Inc. fluctuated between $9.83 and $23.57. Currently, Wall Street analysts expect the stock to reach $43.29 within the next 12 months. Avidity Biosciences Inc. [NASDAQ: RNA] shares were valued at $23.29 at the most recent close of the market. An investor can expect a potential return of 85.87% based on the average RNA price forecast.
Analyzing the RNA fundamentals
According to Avidity Biosciences Inc. [NASDAQ:RNA], the company’s sales were 2.48 billion in the recent quarter, which represents an 13.60% jump. Gross Margin for this corporation currently stands at +93.15% with Operating Margin at -1265.83%, Pretax Margin comes in at -1265.38%, and Net Margin reading is -1265.38%.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 22.04 points at the first support level, and at 20.80 for the second support level. However, for the 1st resistance point, the stock is sitting at 23.99, and for the 2nd resistance point, it is at 24.70.
Avidity Biosciences Inc. [RNA] reported earnings per share of -$0.92 for its fiscal quarter that ended on 6/29/2022. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$0.75/share, meaning a difference of -$0.17 and a surprise factor of -22.70%. By comparison, the stated earnings for the previous quarter ended on 3/30/2022 were -$0.71 per share as compared to estimates of -$0.8 per share, a difference of $0.09 representing a surprise of 11.30%.
Ratios To Look Out For
It is important to note that Avidity Biosciences Inc. [NASDAQ:RNA] has a current ratio of 9.70. In addition, the Quick Ratio stands at 13.86 and the Cash Ratio stands at 13.67. Considering the valuation of this stock, the price to sales ratio is 105.59, the price to book ratio is 2.98.
Transactions by insiders
Recent insider trading involved LEVIN ARTHUR A, Chief Scientific Officer, that happened on Jan 12 when 10000.0 shares were sold. Chief Scientific Officer, LEVIN ARTHUR A completed a deal on Dec 29 to sell 40000.0 shares. Meanwhile, President and CEO Boyce Sarah sold 14855.0 shares on Aug 25.